The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes

Norman E Cameron, Mary Anne Cotter

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Interleukin-6 (IL-6) is a member of the neuropoietic cytokine family and has a multifunctional biological role in regulating the immune response, acute phase reactions, and hematopoiesis. IL-6 is also important in neural development and has neurotrophic actions. The aim was to ascertain whether IL-6 treatment could rectify some of the adverse early changes in neurovascular function in streptozotocin-induced diabetic rats. After 4 weeks of untreated diabetes, rats were treated with IL-6 (1–10 µg/kg thrice weekly) for 4 weeks. Diabetes caused 22% and 22.5% reductions in sciatic nerve motor and saphenous nerve sensory conduction velocity, respectively, which were dose dependently corrected by treatment. Diabetic rats also showed thermal hyperalgesia and tactile allodynia, which were completely corrected by IL-6; however, IL-6 was ineffective against mechanical hyperalgesia. Sciatic nerve endoneurial perfusion was 42.2% reduced by diabetes and blood flow was returned to the nondiabetic range by 10 µg/kg IL-6 treatment. The ED50 values for these actions ranged from 1.2 µg/kg for sensory conduction velocity to 3.2 µg/kg for sciatic nerve perfusion. Thus, IL-6 treatment improved several measures of nerve dysfunction in experimental diabetes, and these effects correlated with a recovery of nerve blood flow. The magnitude of these beneficial effects and the potential joint neurotrophic and vascular action suggests that IL-6 could be a candidate for further evaluation in clinical trials of diabetic neuropathy.
Original languageEnglish
Pages (from-to)23-29
Number of pages7
JournalExperimental Neurology
Volume207
Issue number1
Early online date18 May 2007
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Interleukin-6
Hyperalgesia
Sciatic Nerve
Perfusion
Acute-Phase Reaction
Diabetic Neuropathies
Neural Conduction
Hematopoiesis
Streptozocin
Blood Vessels
Joints
Clinical Trials
Cytokines

Keywords

  • diabetes
  • neuropathy
  • interlekin-6
  • nerve conduction
  • blood flow
  • pain
  • allodynia

Cite this

The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes. / Cameron, Norman E; Cotter, Mary Anne.

In: Experimental Neurology, Vol. 207, No. 1, 09.2007, p. 23-29.

Research output: Contribution to journalArticle

Cameron, Norman E ; Cotter, Mary Anne. / The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes. In: Experimental Neurology. 2007 ; Vol. 207, No. 1. pp. 23-29.
@article{25aa5813b2d844c68e66d5fa3884c3f6,
title = "The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes",
abstract = "Interleukin-6 (IL-6) is a member of the neuropoietic cytokine family and has a multifunctional biological role in regulating the immune response, acute phase reactions, and hematopoiesis. IL-6 is also important in neural development and has neurotrophic actions. The aim was to ascertain whether IL-6 treatment could rectify some of the adverse early changes in neurovascular function in streptozotocin-induced diabetic rats. After 4 weeks of untreated diabetes, rats were treated with IL-6 (1–10 µg/kg thrice weekly) for 4 weeks. Diabetes caused 22{\%} and 22.5{\%} reductions in sciatic nerve motor and saphenous nerve sensory conduction velocity, respectively, which were dose dependently corrected by treatment. Diabetic rats also showed thermal hyperalgesia and tactile allodynia, which were completely corrected by IL-6; however, IL-6 was ineffective against mechanical hyperalgesia. Sciatic nerve endoneurial perfusion was 42.2{\%} reduced by diabetes and blood flow was returned to the nondiabetic range by 10 µg/kg IL-6 treatment. The ED50 values for these actions ranged from 1.2 µg/kg for sensory conduction velocity to 3.2 µg/kg for sciatic nerve perfusion. Thus, IL-6 treatment improved several measures of nerve dysfunction in experimental diabetes, and these effects correlated with a recovery of nerve blood flow. The magnitude of these beneficial effects and the potential joint neurotrophic and vascular action suggests that IL-6 could be a candidate for further evaluation in clinical trials of diabetic neuropathy.",
keywords = "diabetes, neuropathy, interlekin-6, nerve conduction, blood flow, pain, allodynia",
author = "Cameron, {Norman E} and Cotter, {Mary Anne}",
year = "2007",
month = "9",
doi = "10.1016/j.expneurol.2007.05.009",
language = "English",
volume = "207",
pages = "23--29",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",
number = "1",

}

TY - JOUR

T1 - The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes

AU - Cameron, Norman E

AU - Cotter, Mary Anne

PY - 2007/9

Y1 - 2007/9

N2 - Interleukin-6 (IL-6) is a member of the neuropoietic cytokine family and has a multifunctional biological role in regulating the immune response, acute phase reactions, and hematopoiesis. IL-6 is also important in neural development and has neurotrophic actions. The aim was to ascertain whether IL-6 treatment could rectify some of the adverse early changes in neurovascular function in streptozotocin-induced diabetic rats. After 4 weeks of untreated diabetes, rats were treated with IL-6 (1–10 µg/kg thrice weekly) for 4 weeks. Diabetes caused 22% and 22.5% reductions in sciatic nerve motor and saphenous nerve sensory conduction velocity, respectively, which were dose dependently corrected by treatment. Diabetic rats also showed thermal hyperalgesia and tactile allodynia, which were completely corrected by IL-6; however, IL-6 was ineffective against mechanical hyperalgesia. Sciatic nerve endoneurial perfusion was 42.2% reduced by diabetes and blood flow was returned to the nondiabetic range by 10 µg/kg IL-6 treatment. The ED50 values for these actions ranged from 1.2 µg/kg for sensory conduction velocity to 3.2 µg/kg for sciatic nerve perfusion. Thus, IL-6 treatment improved several measures of nerve dysfunction in experimental diabetes, and these effects correlated with a recovery of nerve blood flow. The magnitude of these beneficial effects and the potential joint neurotrophic and vascular action suggests that IL-6 could be a candidate for further evaluation in clinical trials of diabetic neuropathy.

AB - Interleukin-6 (IL-6) is a member of the neuropoietic cytokine family and has a multifunctional biological role in regulating the immune response, acute phase reactions, and hematopoiesis. IL-6 is also important in neural development and has neurotrophic actions. The aim was to ascertain whether IL-6 treatment could rectify some of the adverse early changes in neurovascular function in streptozotocin-induced diabetic rats. After 4 weeks of untreated diabetes, rats were treated with IL-6 (1–10 µg/kg thrice weekly) for 4 weeks. Diabetes caused 22% and 22.5% reductions in sciatic nerve motor and saphenous nerve sensory conduction velocity, respectively, which were dose dependently corrected by treatment. Diabetic rats also showed thermal hyperalgesia and tactile allodynia, which were completely corrected by IL-6; however, IL-6 was ineffective against mechanical hyperalgesia. Sciatic nerve endoneurial perfusion was 42.2% reduced by diabetes and blood flow was returned to the nondiabetic range by 10 µg/kg IL-6 treatment. The ED50 values for these actions ranged from 1.2 µg/kg for sensory conduction velocity to 3.2 µg/kg for sciatic nerve perfusion. Thus, IL-6 treatment improved several measures of nerve dysfunction in experimental diabetes, and these effects correlated with a recovery of nerve blood flow. The magnitude of these beneficial effects and the potential joint neurotrophic and vascular action suggests that IL-6 could be a candidate for further evaluation in clinical trials of diabetic neuropathy.

KW - diabetes

KW - neuropathy

KW - interlekin-6

KW - nerve conduction

KW - blood flow

KW - pain

KW - allodynia

U2 - 10.1016/j.expneurol.2007.05.009

DO - 10.1016/j.expneurol.2007.05.009

M3 - Article

VL - 207

SP - 23

EP - 29

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -